Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Abstract:

Importance:In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. Objective:To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib. Design, Setting, and Participants:This randomized clinical trial began as a phase 3 trial on July 14, 2010, and continued until March 24, 2016, with a median follow-up of 3.3 years and a clinical cutoff date for this report of May 5, 2017. Patients with mRCC of clear cell subtype, resectable primary tumor, and 3 or fewer surgical risk factors were studied. Interventions:Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy. Main Outcomes and Measures:Progression-free survival was the primary end point, which needed a sample size of 458 patients. Because of poor accrual, the independent data monitoring committee endorsed reporting the intention-to-treat 28-week progression-free rate (PFR) instead. Overall survival (OS), adverse events, and postoperative progression were secondary end points. Results:The study closed after 5.7 years with 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years). The 28-week PFR was 42% in the immediate CN arm (n = 50) and 43% in the deferred CN arm (n = 49) (P = .61). The intention-to-treat OS hazard ratio of deferred vs immediate CN was 0.57 (95% CI, 0.34-0.95; P = .03), with a median OS of 32.4 months (95% CI, 14.5-65.3 months) in the deferred CN arm and 15.0 months (95% CI, 9.3-29.5 months) in the immediate CN arm. In the deferred CN arm, 48 of 49 patients (98%; 95% CI, 89%-100%) received sunitinib vs 40 of 50 (80%; 95% CI, 67%-89%) in the immediate arm. Systemic progression before planned CN in the deferred CN arm resulted in a per-protocol recommendation against nephrectomy in 14 patients (29%; 95% CI, 18%-43%). Conclusions and Relevance:Deferred CN did not improve the 28-week PFR. With the deferred approach, more patients received sunitinib and OS results were higher. Pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN. This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib. Trial Registration:ClinicalTrials.gov identifier: NCT01099423.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Bex A,Mulders P,Jewett M,Wagstaff J,van Thienen JV,Blank CU,van Velthoven R,Del Pilar Laguna M,Wood L,van Melick HHE,Aarts MJ,Lattouf JB,Powles T,de Jong Md PhD IJ,Rottey S,Tombal B,Marreaud S,Collette S,Collette L,

doi

10.1001/jamaoncol.2018.5543

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

164-170

issue

2

eissn

2374-2437

issn

2374-2445

pii

2718007

journal_volume

5

pub_type

杂志文章,多中心研究,随机对照试验
  • Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

    abstract:Importance:Hereditary cancer syndromes infer high cancer risks and require intensive cancer surveillance, yet the prevalence and spectrum of these conditions among unselected patients with early-onset colorectal cancer (CRC) is largely undetermined. Objective:To determine the frequency and spectrum of cancer susceptib...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.5194

    authors: Pearlman R,Frankel WL,Swanson B,Zhao W,Yilmaz A,Miller K,Bacher J,Bigley C,Nelsen L,Goodfellow PJ,Goldberg RM,Paskett E,Shields PG,Freudenheim JL,Stanich PP,Lattimer I,Arnold M,Liyanarachchi S,Kalady M,Heald B,Gre

    更新日期:2017-04-01 00:00:00

  • Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.

    abstract:IMPORTANCE:BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually. OBJECTIVE:To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services a...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3048

    authors: Armstrong J,Toscano M,Kotchko N,Friedman S,Schwartz MD,Virgo KS,Lynch K,Andrews JE,Aguado Loi CX,Bauer JE,Casares C,Bourquardez Clark E,Kondoff MR,Molina AD,Abdollahian M,Walker G,Sutphen R

    更新日期:2015-12-01 00:00:00

  • Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.

    abstract:Importance:Human papillomavirus (HPV) is a common sexually transmitted infection that is a major cause of noncervical anogenital and oropharyngeal cancers. Prophylactic HPV vaccine is available for primary prevention. However, the population prevalence data for male genital HPV infection is not well known, while the HP...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6192

    authors: Han JJ,Beltran TH,Song JW,Klaric J,Choi YS

    更新日期:2017-06-01 00:00:00

  • Aspirin Use and Risk of Colorectal Cancer Among Older Adults.

    abstract:Importance:Although aspirin is recommended for the prevention of colorectal cancer (CRC) among adults aged 50 to 59 years, recent data from a randomized clinical trial suggest a lack of benefit and even possible harm among older adults. Objective:To examine the association between aspirin use and the risk of incident ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.7338

    authors: Guo CG,Ma W,Drew DA,Cao Y,Nguyen LH,Joshi AD,Ng K,Ogino S,Meyerhardt JA,Song M,Leung WK,Giovannucci EL,Chan AT

    更新日期:2021-01-21 00:00:00

  • Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.

    abstract:Importance:The evidence for concurrent chemoradiotherapy (CT-RT) in International Federation of Gynecology and Obstetrics (FIGO) stage IIIB squamous cell carcinoma of the uterine cervix is not robust. This study reports the final results of a randomized clinical trial of concurrent cisplatin-based CT-RT and radiotherap...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.5179

    authors: Shrivastava S,Mahantshetty U,Engineer R,Chopra S,Hawaldar R,Hande V,Kerkar RA,Maheshwari A,Shylasree TS,Ghosh J,Bajpai J,Gurram L,Gulia S,Gupta S,Gynecologic Disease Management Group.

    更新日期:2018-04-01 00:00:00

  • Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer.

    abstract:Importance:Sarcopenia (low muscle mass), poor muscle quality (low muscle radiodensity), and excess adiposity derived from computed tomography (CT) has been related to higher mortality in patients with metastatic breast cancer, but the association with prognosis in patients with nonmetastatic breast cancer is unknown. ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.0137

    authors: Caan BJ,Cespedes Feliciano EM,Prado CM,Alexeeff S,Kroenke CH,Bradshaw P,Quesenberry CP,Weltzien EK,Castillo AL,Olobatuyi TA,Chen WY

    更新日期:2018-06-01 00:00:00

  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

    abstract:Importance:Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective:To evaluate the association of pCR with event-free survival (EFS) and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2535

    authors: I-SPY2 Trial Consortium.,Yee D,DeMichele AM,Yau C,Isaacs C,Symmans WF,Albain KS,Chen YY,Krings G,Wei S,Harada S,Datnow B,Fadare O,Klein M,Pambuccian S,Chen B,Adamson K,Sams S,Mhawech-Fauceglia P,Magliocco A,Feldma

    更新日期:2020-09-01 00:00:00

  • Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage.

    abstract:IMPORTANCE:Instituting widespread measurement of outcomes for cancer hospitals using administrative data is difficult owing to lack of cancer-specific information such as disease stage. OBJECTIVE:To evaluate the performance of hospitals that treat patients with cancer using Medicare data for outcome ascertainment and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3151

    authors: Pfister DG,Rubin DM,Elkin EB,Neill US,Duck E,Radzyner M,Bach PB

    更新日期:2015-12-01 00:00:00

  • Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

    abstract:Importance:To date, there is no well-defined standard of care for early-stage pediatric Hodgkin lymphoma (HL), which may include chemotherapy alone or combined modality therapy (CMT) with chemotherapy followed by radiotherapy. Although the use of radiotherapy in pediatric HL is decreasing, this strategy remains controv...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5911

    authors: Jhawar SR,Rivera-Núñez Z,Drachtman R,Cole PD,Hoppe BS,Parikh RR

    更新日期:2019-05-01 00:00:00

  • The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.

    abstract:Importance:For more than a decade, sorafenib has been the only systemic treatment option for patients with advanced hepatocellular carcinoma (HCC). However, rapid progress over the past few years led to approval of other angiogenesis inhibitors and several immune checkpoint blockers (ICBs) that have been added to the t...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3381

    authors: Pinter M,Jain RK,Duda DG

    更新日期:2021-01-01 00:00:00

  • Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.

    abstract:Importance:Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosensitivity of the myxoid liposarcoma subtype might offer the possibility to reduce morbidity. Objective:...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.5865

    authors: Lansu J,Bovée JVMG,Braam P,van Boven H,Flucke U,Bonenkamp JJ,Miah AB,Zaidi SH,Thway K,Bruland ØS,Baldini EH,Jebsen NL,Scholten AN,van den Ende PLA,Krol ADG,Ubbels JF,van der Hage JA,van Werkhoven E,Klomp HM,van der

    更新日期:2021-01-01 00:00:00

  • Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

    abstract:Importance:The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and s...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.3361

    authors: Slovin S,Clark W,Carles J,Krivoshik A,Park JW,Wang F,George D

    更新日期:2018-05-01 00:00:00

  • Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer.

    abstract:Importance:Black individuals are underrepresented in cancer clinical trials. Objective:To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. Design, S...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3697

    authors: Senft N,Hamel LM,Manning MA,Kim S,Penner LA,Moore TF,Carducci MA,Heath EI,Lansey DG,Albrecht TL,Wojda M,Jordan A,Eggly S

    更新日期:2020-09-17 00:00:00

  • Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.

    abstract:Importance:Conventional adjuvant radiotherapy for breast cancer given daily for several weeks is onerous and expensive. Some patients may be obliged to choose a mastectomy instead, and some may forgo radiotherapy altogether. We proposed a clinical trial to test whether radiotherapy could be safely limited to the tumor ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2020.0249

    authors: Vaidya JS,Bulsara M,Saunders C,Flyger H,Tobias JS,Corica T,Massarut S,Wenz F,Pigorsch S,Alvarado M,Douek M,Eiermann W,Brew-Graves C,Williams N,Potyka I,Roberts N,Bernstein M,Brown D,Sperk E,Laws S,Sütterlin M,Lu

    更新日期:2020-07-01 00:00:00

  • Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.

    abstract:Importance:Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have achieved success in treating a number of malignancies. However, only a subset of patients responds to these therapies, and optimization of patient sele...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.2214

    authors: Dijkstra KK,Voabil P,Schumacher TN,Voest EE

    更新日期:2016-11-01 00:00:00

  • Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

    abstract:Importance:A significant proportion of patients with early-stage triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Sequencing of circulating tumor DNA (ctDNA) after surgery, along with enumeration of circulating tumor cells (CTCs), may be used to detect minimal residual disease and assess ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2295

    authors: Radovich M,Jiang G,Hancock BA,Chitambar C,Nanda R,Falkson C,Lynce FC,Gallagher C,Isaacs C,Blaya M,Paplomata E,Walling R,Daily K,Mahtani R,Thompson MA,Graham R,Cooper ME,Pavlick DC,Albacker LA,Gregg J,Solzak JP,C

    更新日期:2020-09-01 00:00:00

  • Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

    abstract:IMPORTANCE:Hepatocellular carcinoma (HCC) has the second-highest cancer-related mortality rate in the world because most patients are diagnosed at an intermediate to advanced stage when surgery is not suitable. Transcatheter arterial chemoembolization (TACE) is currently considered a first-line therapy for unresectable...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1001/jamaoncol.2015.2189

    authors: Huo YR,Eslick GD

    更新日期:2015-09-01 00:00:00

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

    abstract:Importance:Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors. The rate and outcome of HPD in advanced non-small cell lung cancer (NSCLC) are unknown. Objectives:To i...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.3676

    authors: Ferrara R,Mezquita L,Texier M,Lahmar J,Audigier-Valette C,Tessonnier L,Mazieres J,Zalcman G,Brosseau S,Le Moulec S,Leroy L,Duchemann B,Lefebvre C,Veillon R,Westeel V,Koscielny S,Champiat S,Ferté C,Planchard D,Remon

    更新日期:2018-11-01 00:00:00

  • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.

    abstract:Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this diseas...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.0219

    authors: Frezza AM,Jones RL,Lo Vullo S,Asano N,Lucibello F,Ben-Ami E,Ratan R,Teterycz P,Boye K,Brahmi M,Palmerini E,Fedenko A,Vincenzi B,Brunello A,Desar IME,Benjamin RS,Blay JY,Broto JM,Casali PG,Gelderblom H,Grignani G,

    更新日期:2018-09-01 00:00:00

  • Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

    abstract:Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.0465

    authors: Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

    更新日期:2017-11-01 00:00:00

  • A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.

    abstract:Importance:Multiparametric magnetic resonance imaging (MRI) in conjunction with MRI-transrectal ultrasound (TRUS) fusion-guided biopsies have improved the detection of prostate cancer. It is unclear whether MRI itself adds additional value to multivariable prediction models based on clinical parameters. Objective:To d...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.5667

    authors: Mehralivand S,Shih JH,Rais-Bahrami S,Oto A,Bednarova S,Nix JW,Thomas JV,Gordetsky JB,Gaur S,Harmon SA,Siddiqui MM,Merino MJ,Parnes HL,Wood BJ,Pinto PA,Choyke PL,Turkbey B

    更新日期:2018-05-01 00:00:00

  • Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women.

    abstract:Importance:Colorectal cancer (CRC) incidence and mortality among individuals younger than 50 years (early-onset CRC) are increasing. The reasons for such increases are largely unknown, although the increasing prevalence of obesity may be partially responsible. Objective:To investigate prospectively the association bet...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.4280

    authors: Liu PH,Wu K,Ng K,Zauber AG,Nguyen LH,Song M,He X,Fuchs CS,Ogino S,Willett WC,Chan AT,Giovannucci EL,Cao Y

    更新日期:2019-01-01 00:00:00

  • Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

    abstract:Importance:Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with a median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) of high-dose chemotherapy may have potential benefit in these patients. Objective:To evaluate clinical outcomes when HAI chemotherapy is combined wit...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2019.3718

    authors: Cercek A,Boerner T,Tan BR,Chou JF,Gönen M,Boucher TM,Hauser HF,Do RKG,Lowery MA,Harding JJ,Varghese AM,Reidy-Lagunes D,Saltz L,Schultz N,Kingham TP,D'Angelica MI,DeMatteo RP,Drebin JA,Allen PJ,Balachandran VP,Lim

    更新日期:2019-10-31 00:00:00

  • Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

    abstract:IMPORTANCE:The anti-PD-1 therapeutic antibody, nivolumab, has demonstrated clinical activity in patients with advanced melanoma. The activity of nivolumab in subgroups of patients with tumors which have wild-type BRAF kinase vs patients with tumors having mutant BRAF has not systematically been explored in a large data...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.1184

    authors: Larkin J,Lao CD,Urba WJ,McDermott DF,Horak C,Jiang J,Wolchok JD

    更新日期:2015-07-01 00:00:00

  • BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.

    abstract:IMPORTANCE:BRCA testing is recommended for young women diagnosed as having breast cancer, but little is known about decisions surrounding testing and how results may influence treatment decisions in young patients. OBJECTIVES:To describe the use of BRCA testing and to evaluate how concerns about genetic risk and use o...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.5941

    authors: Rosenberg SM,Ruddy KJ,Tamimi RM,Gelber S,Schapira L,Come S,Borges VF,Larsen B,Garber JE,Partridge AH

    更新日期:2016-06-01 00:00:00

  • Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

    abstract:Importance:Three years of adjuvant imatinib mesylate therapy is associated with reduced recurrence rates and improved overall survival in patients with high-risk primary gastrointestinal stromal tumor (GIST) compared with patients who receive 1 year of treatment. The impact of a longer duration of therapy is unknown. ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.4060

    authors: Raut CP,Espat NJ,Maki RG,Araujo DM,Trent J,Williams TF,Purkayastha DD,DeMatteo RP

    更新日期:2018-12-01 00:00:00

  • Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

    abstract:Importance:Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-cell therapy, was the first US Food and Drug Administration-approved, genetically engineered T-cell therapy for adults with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy. There has not ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2019.3869

    authors: Locke FL,Go WY,Neelapu SS

    更新日期:2020-02-01 00:00:00

  • Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.

    abstract:Importance:Why some triple-negative breast cancers (TNBCs) have high and others have low immune cell infiltration is unknown. Understanding how immune surveillance shapes the cancer genome could help in the selection of patients and the development of more effective immunotherapy strategies. Objective:To examine the a...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.2140

    authors: Karn T,Jiang T,Hatzis C,Sänger N,El-Balat A,Rody A,Holtrich U,Becker S,Bianchini G,Pusztai L

    更新日期:2017-12-01 00:00:00

  • Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

    abstract:Importance:The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors. Objective:To perform a validation study of the AJCC eighth edition prognostic stage in a single-institut...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.4298

    authors: Weiss A,Chavez-MacGregor M,Lichtensztajn DY,Yi M,Tadros A,Hortobagyi GN,Giordano SH,Hunt KK,Mittendorf EA

    更新日期:2018-02-01 00:00:00

  • Time to Surgery and Breast Cancer Survival in the United States.

    abstract:IMPORTANCE:Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association. OBJECTIVE:To investigate the relationship between the time from diagnosis to breast cancer surgery and survival, usin...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.4508

    authors: Bleicher RJ,Ruth K,Sigurdson ER,Beck JR,Ross E,Wong YN,Patel SA,Boraas M,Chang EI,Topham NS,Egleston BL

    更新日期:2016-03-01 00:00:00